Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Mind Medicine Inc (MMED.NE)

Mind Medicine Inc (MMED.NE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [Cboe CA]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [Cboe CA]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 1,050,465
  • Shares Outstanding, K 70,501
  • Annual Sales, $ 0 K
  • Annual Income, $ -108,679 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta 3.49
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 9.91
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -2.44
  • Most Recent Earnings $-0.59 on 11/02/23
  • Next Earnings Date N/A
  • Annual Dividend & Yield 0.00 (N/A)
  • Most Recent Dividend N/A on N/A
  • Sector N/A
  • INDUSTRY GROUPING N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.1900 +46.22%
on 03/12/24
16.4000 -9.15%
on 04/04/24
+1.8600 (+14.26%)
since 03/08/24
3-Month
4.7000 +217.02%
on 01/22/24
16.4000 -9.15%
on 04/04/24
+9.2600 (+164.18%)
since 01/10/24
52-Week
3.3000 +351.52%
on 11/20/23
16.4000 -9.15%
on 04/04/24
+10.8200 (+265.20%)
since 04/10/23

Most Recent Stories

More News
Global Neuro-Psychiatric Disorders & Treatment Market Projected to Reach $166 Billion by 2032

CMPS : 5.33 (+2.40%)
CYBN.NE : 8.6500 (+4.85%)
ATAI : 3.96 (-1.00%)
MMED.NE : 14.9000 (+9.48%)
SAGE : 8.68 (-0.23%)
MNMD : 11.34 (-0.09%)
CYBN : 6.07 (+2.36%)
Global Neuro-Psychiatric Disorders & Treatment Market Projected to Reach $166 Billion by 2032

EQNX::TICKER_START (NYSE:CYBN),(NEO:CYBN),(NASDAQ:CMPS),(NASDAQ:SAGE),(NASDAQ:MNMD),(NASDAQ:ATAI),(NEO:MMED) EQNX::TICKER_END

CMPS : 5.33 (+2.40%)
CYBN.NE : 8.6500 (+4.85%)
ATAI : 3.96 (-1.00%)
MMED.NE : 14.9000 (+9.48%)
SAGE : 8.68 (-0.23%)
MNMD : 11.34 (-0.09%)
CYBN : 6.07 (+2.36%)
How Psychedelic-Based Therapeutics Are Advancing in Treating Generalized Anxiety Disorder (GAD) Condition

EQNX::TICKER_START (NYSE:CYBN),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:SEEL),(NASDAQ:ATAI) EQNX::TICKER_END

CMPS : 5.33 (+2.40%)
CYBN.NE : 8.6500 (+4.85%)
ATAI : 3.96 (-1.00%)
MMED.NE : 14.9000 (+9.48%)
MNMD : 11.34 (-0.09%)
CYBN : 6.07 (+2.36%)
SEEL : 0.3900 (-27.79%)
Global Psychedelic Therapeutics Market Size Expected To Reach $13.29 Billion By The Year 2031

EQNX::TICKER_START (NYSE:CYBN),NEO:CYBN),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:SEEL),(OTCQX:NUMIF) EQNX::TICKER_END

NUMIF : 0.0303 (-16.99%)
CMPS : 5.33 (+2.40%)
CYBN.NE : 8.6500 (+4.85%)
MMED.NE : 14.9000 (+9.48%)
NUMI.TO : 0.0500 (+42.86%)
MNMD : 11.34 (-0.09%)
CYBN : 6.07 (+2.36%)
SEEL : 0.3900 (-27.79%)
MindMed Reports First Quarter 2023 Financial Results and Business Highlights

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders,...

MMED.NE : 14.9000 (+9.48%)
MNMD : 11.34 (-0.09%)
MindMed Sends Letter to Shareholders Highlighting Company’s Positive Momentum and Value-Enhancing Strategy

The Board of Directors (the “Board”) of Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product...

FBRX : 14.49 (+2.91%)
JAZZ : 170.09 (+20.57%)
MMED.NE : 14.9000 (+9.48%)
ALC : 76.61 (-1.34%)
INCY : 104.17 (+0.02%)
SGEN : 228.74 (-0.07%)
MNMD : 11.34 (-0.09%)
PFE : 25.08 (+0.08%)
MindMed to Host Conference Call and Webcast to Discuss First Quarter 2023 Financial Results and Provide Business Update

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or "MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders,...

MMED.NE : 14.9000 (+9.48%)
MNMD : 11.34 (-0.09%)
MindMed to Participate in May Investor Conferences

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders,...

MMED.NE : 14.9000 (+9.48%)
MNMD : 11.34 (-0.09%)
MindMed Files Preliminary Proxy Statement for 2023 Annual Meeting

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders,...

FBRX : 14.49 (+2.91%)
MMED.NE : 14.9000 (+9.48%)
INCY : 104.17 (+0.02%)
SGEN : 228.74 (-0.07%)
MNMD : 11.34 (-0.09%)
BMY : 46.81 (+0.34%)
MindMed Collaborators Announce Positive Topline Data from Phase 2 Trial of Lysergide (LSD) in Major Depressive Disorder (MDD)

Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, announced...

MMED.NE : 14.9000 (+9.48%)
MNMD : 11.34 (-0.09%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically...

See More

Key Turning Points

3rd Resistance Point 19.5833
2nd Resistance Point 17.3267
1st Resistance Point 16.1133
Last Price 14.9000
1st Support Level 12.6433
2nd Support Level 10.3867
3rd Support Level 9.1733

See More

52-Week High 16.4000
Last Price 14.9000
Fibonacci 61.8% 11.3958
Fibonacci 50% 9.8500
Fibonacci 38.2% 8.3042
52-Week Low 3.3000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar